TRANSLATE BIO INC's ticker is TBIO and the CUSIP is 89374L104. A total of 48 filers reported holding TRANSLATE BIO INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $102,945,000 | +68.6% | 3,738,001 | +0.9% | 0.19% | +62.7% |
| Q1 2021 | $61,068,000 | +20.8% | 3,703,351 | +35.0% | 0.12% | +14.6% |
| Q4 2020 | $50,542,000 | +39.6% | 2,742,379 | +3.1% | 0.10% | +21.2% |
| Q3 2020 | $36,202,000 | -24.0% | 2,659,915 | +0.1% | 0.08% | -28.0% |
| Q2 2020 | $47,633,000 | +108.7% | 2,658,099 | +16.1% | 0.12% | +76.1% |
| Q1 2020 | $22,823,000 | +33.7% | 2,289,162 | +9.2% | 0.07% | +76.3% |
| Q4 2019 | $17,066,000 | -15.9% | 2,096,528 | +2.4% | 0.04% | -24.0% |
| Q3 2019 | $20,284,000 | +42.1% | 2,046,775 | +81.1% | 0.05% | +42.9% |
| Q2 2019 | $14,272,000 | +23.9% | 1,130,000 | 0.0% | 0.04% | +25.0% |
| Q1 2019 | $11,515,000 | +35.9% | 1,130,000 | 0.0% | 0.03% | +21.7% |
| Q4 2018 | $8,475,000 | +5.9% | 1,130,000 | +41.2% | 0.02% | +21.1% |
| Q3 2018 | $8,000,000 | -11.0% | 800,000 | +12.6% | 0.02% | -26.9% |
| Q2 2018 | $8,984,000 | – | 710,195 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Advisors, Inc. | 2,656,517 | $48,960,000 | 10.98% |
| Copernicus Capital Management, LLC | 12,091 | $223,000 | 3.48% |
| FRAZIER MANAGEMENT LLC | 2,182,789 | $40,229,000 | 3.10% |
| Baupost Group | 18,044,239 | $326,236,000 | 3.01% |
| DAFNA Capital Management LLC | 225,393 | $4,154,000 | 1.24% |
| RTW INVESTMENTS, LP | 2,978,427 | $54,892,000 | 0.92% |
| MARATHON CAPITAL MANAGEMENT | 143,275 | $2,640,000 | 0.78% |
| Bain Capital Public Equity Management II, LLC | 627,387 | $11,563,000 | 0.59% |
| Artal Group S.A. | 1,200,000 | $22,116,000 | 0.48% |
| Birchview Capital, LP | 30,000 | $553,000 | 0.32% |